Comparative Pharmacology
Head-to-head clinical analysis: JAIMIESS versus YAELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JAIMIESS versus YAELA.
JAIMIESS vs YAELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
Yaela is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity, contributing to contraceptive efficacy and reducing fluid retention.
100 mg orally once daily with food.
The standard adult dose of Yaela (ethinyl estradiol/levonorgestrel) for oral contraception is 1 tablet (containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) taken orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal elimination half-life is 12 ± 3 hours (range 8-16 hours) in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Renal excretion of unchanged drug accounts for approximately 70% of the administered dose; biliary/fecal excretion accounts for 30%.
Category C
Category C
Oral Contraceptive, Combined
Oral Contraceptive